QuantumBio specializes in advanced software solutions for drug discovery and molecular design, focusing on enhancing lead optimization and reducing risks in drug research and development. Their flagship product, the DivCon Discovery Suite, integrates structural biology and computer-aided drug design (CADD) to provide fast, accurate, and user-friendly tools. This suite includes features for refining X-ray crystallography structures and employing high-throughput methods for drug design, enabling researchers to rapidly discover and analyze potential drug candidates. The software is designed to be easily integrated into existing workflows, offering robust computational chemistry toolkits that simulate molecular interactions with high precision.

One of the standout technologies offered by QuantumBio is XModeScore, which allows for the accurate determination of protein-ligand binding states and enhances structure-based drug discovery. This tool leverages quantum mechanics to refine structures and identify tautomers, protomers, and other critical molecular states, even at lower resolutions. Additionally, the DivCon plugin enhances X-ray crystallography refinement by utilizing a mixed quantum mechanics/molecular mechanics (QM/MM) approach, which improves the accuracy of ligand conformations and reduces biases associated with traditional methods. Overall, QuantumBio's innovative technologies aim to revolutionize the drug discovery process by providing researchers with powerful, precise, and efficient tools.

United States

QuantumBio is a software and services company that offers a powerful suite of products built on cutting-edge science to provide innovative technical solutions to the life sciences with high accuracy and performance.

QuantumBio

Company Details